Sana Biotechnology (SANA) Competitors

Fusion Pharmaceuticals (NASDAQ:FUSN) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Is FUSN or SANA more profitable?

Sana Biotechnology has a net margin of 0.00% compared to Sana Biotechnology's net margin of -4,136.55%. Sana Biotechnology's return on equity of -46.59% beat Fusion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fusion Pharmaceuticals	-4,136.55%	-46.59%	-35.34%
Sana Biotechnology	N/A	-88.36%	-47.89%

Does the MarketBeat Community favor FUSN or SANA?

Fusion Pharmaceuticals received 30 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 47.83% of users gave Sana Biotechnology an outperform vote.

Company	Underperform	Outperform
Fusion Pharmaceuticals	Outperform Votes 41 64.06%	Underperform Votes 23 35.94%
Sana Biotechnology	Outperform Votes 11 47.83%	Underperform Votes 12 52.17%

Does the media favor FUSN or SANA?

In the previous week, Fusion Pharmaceuticals had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 11 mentions for Fusion Pharmaceuticals and 1 mentions for Sana Biotechnology. Fusion Pharmaceuticals' average media sentiment score of 0.59 beat Sana Biotechnology's score of 0.09 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fusion Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of FUSN or SANA?

72.9% of Fusion Pharmaceuticals shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 7.8% of Fusion Pharmaceuticals shares are held by insiders. Comparatively, 34.9% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has higher valuation & earnings, FUSN or SANA?

Fusion Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fusion Pharmaceuticals	$2.07M	870.33	-$94.90M	-$1.47	-14.44
Sana Biotechnology	N/A	N/A	-$283.26M	-$1.47	-5.21

Which has more volatility & risk, FUSN or SANA?

Fusion Pharmaceuticals has a beta of -0.72, suggesting that its share price is 172% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Do analysts rate FUSN or SANA?

Fusion Pharmaceuticals presently has a consensus target price of $20.25, suggesting a potential downside of 4.57%. Sana Biotechnology has a consensus target price of $11.67, suggesting a potential upside of 52.31%. Given Fusion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Fusion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fusion Pharmaceuticals	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
Sana Biotechnology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Sana Biotechnology beats Fusion Pharmaceuticals on 9 of the 16 factors compared between the two stocks.